VEGFB was not significantly changed in CRC with KRAS mutation, but was slightly over-expressed in CRC tissue with the KRAS wild-type (FC = 1.06 (95% CI 1.02–1.10) suggesting the potential response only in the KRAS wild-type. The gene discussed is KRAS; the disease is colorectal carcinoma.